SCHEMBL5832003

SCHEMBL5832003

N#Cc1cc(-c2nc3ccccc3o2)ccc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 1/20 0.52
KDM6A O15550 1/20 0.52
PTGS2 P35354 1/20 0.52
NPC1 O15118 7/20 0.50
RAB9A P51151 5/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ATM Q13315 1/20 0.50
ESR1 P03372 7/20 0.49
ESR2 Q92731 7/20 0.49
MAPT P10636 3/20 0.49
SNCA P37840 1/20 0.49
KDM4E B2RXH2 5/20 0.48
ALDH1A1 P00352 5/20 0.48
HPGD P15428 5/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
TP53 P04637 3/20 0.48
NFKB1 P19838 2/20 0.47
STAT1 P42224 2/20 0.47
NFKB2 Q00653 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832739 0.81 PTGS2 (0.52) PTGS2NPC1RAB9AMEN1KMT2A
SCHEMBL5832479 0.80 NPC1 (0.71) PTGS2NPC1RAB9AMEN1KMT2A
SCHEMBL11376453 0.80 NPC1 (0.47) NPC1RAB9AMEN1KMT2AATM
SCHEMBL25864467 0.79 RAB9A (0.50) PTGS2NPC1RAB9AMEN1KMT2A
SCHEMBL11320611 0.78 NPC1 (0.59) KDM6BKDM6APTGS2NPC1RAB9A
SCHEMBL5831992 0.78 PTGS2 (0.80) KDM6BKDM6APTGS2NPC1RAB9A
SCHEMBL3317791 0.78 KDM6B (0.63) KDM6BKDM6APTGS2NPC1RAB9A
SCHEMBL5832486 0.77 NPC1 (0.71) PTGS2NPC1RAB9AMEN1KMT2A
SCHEMBL5832068 0.77 ESR2 (0.49) KDM6BKDM6APTGS2NPC1RAB9A
SCHEMBL5831976 0.77 NPC1 (0.58) NPC1RAB9AMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 KDM6B 3945/4885KDM6A 4179/4885PTGS2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.